Maze Therapeutics (MAZE) Total Liabilities (2024 - 2026)

Maze Therapeutics has disclosed Total Liabilities across 3 years of filings, most recently posting $78.0 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $78.0 million, up 91.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.0 million (up 91.33% YoY), and the FY2025 annual result was $42.2 million, down 3.38% from the prior year.
• Total Liabilities came in at $78.0 million for Q1 2026 at Maze Therapeutics, up from $42.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $403.7 million in Q1 2024 to a low of $40.8 million in Q1 2025.
• The 3-year median for Total Liabilities is $43.6 million (2024), against an average of $137.7 million.
• Across the five-year window, Total Liabilities slumped 89.9% in 2025 and surged 91.33% in 2026, its largest moves.
• Maze Therapeutics' Total Liabilities stood at $43.6 million in 2024, then retreated by 3.38% to $42.2 million in 2025, then soared by 85.03% to $78.0 million in 2026.
• The last three Total Liabilities figures came in at $78.0 million (Q1 2026), $42.2 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.